⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25283008 | 1.00 | — | — | |
| SCHEMBL29821700 | 1.00 | — | — | |
| SCHEMBL21735532 | 0.81 | — | — | |
| SCHEMBL12493812 | 0.74 | CETP (0.39) | — | |
| SCHEMBL28557995 | 0.73 | — | — | |
| SCHEMBL27761804 | 0.73 | — | — | |
| SCHEMBL23544634 | 0.71 | — | — | |
| SCHEMBL1425948 | 0.71 | — | — | |
| SCHEMBL24379479 | 0.71 | — | — | |
| SCHEMBL1426213 | 0.71 | DPP4 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655304-A1 | MACROCYCLIC AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | Yuhan Corporation (KR) | 2025-12-03 | — | — | EP | disclosed |
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2025-10-30 | — | — | US | disclosed |
| US-20250188020-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | ACUITAS THERAPEUTICS INC (CA) | 2025-06-12 | — | — | US | disclosed |
| US-20250059131-A1 | FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES | ACUITAS THERAPEUTICS INC (CA) | 2025-02-20 | — | — | US | disclosed |
| US-12129223-B2 | Lipids for use in lipid nanoparticle formulations | Acuitas Therapeutics, Inc. (CA) | 2024-10-29 | — | — | US | disclosed |
| EP-4448482-A2 | FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES | Acuitas Therapeutics, Inc. (CA) | 2024-10-23 | — | — | EP | disclosed |
| EP-4448485-A2 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2024-10-23 | — | — | EP | disclosed |
| WO-2024177362-A1 | MACROCYCLIC AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | YUHAN CORPORATION (KR) | 2024-08-29 | — | — | WO | disclosed |
| US-20230295075-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-09-21 | — | — | US | disclosed |
| US-20230295075-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-09-21 | — | — | US | disclosed |
| US-20230295075-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-09-21 | — | — | US | disclosed |
| WO-2023114943-A2 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114943-A2 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114937-A2 | FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES | Acuitas Therapeutics, Inc. (CA) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114937-A2 | FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES | Acuitas Therapeutics, Inc. (CA) | 2023-06-22 | — | — | WO | disclosed |
| US-11427578-B1 | Substituted pyrrolopyridine-derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-08-30 | — | — | US | disclosed |
| US-20220119419-A1 | BYCYCLIC JAK INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2022-04-21 | — | — | US | disclosed |
| WO-2021094209-A1 | SUBSTITUTED PYRROLO TRIAZINE CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN EP3 RECEPTOR ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | WO | disclosed |
| WO-2020198583-A1 | BICYCLIC JAK INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2020-10-01 | — | — | WO | disclosed |